The results of a successful collaboration between Molecure, the Medical University of Warsaw (MUW), and the Structural Biology Core Facility (SBCF) at the Małopolska Centre of Biotechnology were recently published in the Journal of Medicinal Chemistry.

Led by Molecure, the project focused on the discovery and optimization of selective USP7 inhibitors. Scientists from SBCF provided key support through structural analysis using macromolecular crystallography. Their contribution delivered detailed insights into the binding modes of the inhibitors, supporting SAR-driven optimization of the lead compound, OAT-4828.

The study identifies OAT-4828 as a potent USP7 inhibitor that enhances T-cell killing capacity and shows significant antileukemic activity in vivo. It also highlights USP7 inhibition as a promising upstream strategy for modulating the p53–MDM2 axis.

“It was a pleasure to contribute our facility’s expertise to this high-impact study, illustrating how specialized structural biology services can support innovative drug discovery pipelines,” said dr hab. Piotr Wilk, Head of the Structural Biology Core Facility at MCB.

Read the full text:
https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00407